Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life.

Lombardi C, Bagnasco D, Caruso C, D'Amato M, Menzella F, Milanese M, Senna G, Canonica GW, Passalacqua G.

Pulm Pharmacol Ther. 2019 Feb;54:87-89. doi: 10.1016/j.pupt.2018.12.003. Epub 2018 Dec 29.

PMID:
30597278
2.

Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma.

Katsaounou P, Odemyr M, Spranger O, Hyland ME, Kroegel C, Conde LG, Gore R, Menzella F, Domingo Ribas C, Morais-Almeida M, Gasser M, Kasujee I.

ERJ Open Res. 2018 Dec 21;4(4). pii: 00076-2018. doi: 10.1183/23120541.00076-2018. eCollection 2018 Oct. Erratum in: ERJ Open Res. 2019 Feb 01;5(1):.

3.

Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective.

Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J, Menzella F, Blasi F, Aliberti S, Restrepo MI; GLIMP Study Group.

BMC Infect Dis. 2018 Dec 18;18(1):677. doi: 10.1186/s12879-018-3565-z.

4.

Severe refractory asthma: current treatment options and ongoing research.

Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M.

Drugs Context. 2018 Dec 5;7:212561. doi: 10.7573/dic.212561. eCollection 2018. Review.

5.

The Severe Asthma Network in Italy: Findings and Perspectives.

Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, Senna G, Canonica GW; SANI Network.

J Allergy Clin Immunol Pract. 2018 Oct 25. pii: S2213-2198(18)30673-1. doi: 10.1016/j.jaip.2018.10.016. [Epub ahead of print]

PMID:
30368004
6.

Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report.

Menzella F, Codeluppi L, Lusuardi M, Galeone C, Valzania F, Facciolongo N.

Multidiscip Respir Med. 2018 Sep 1;13:32. doi: 10.1186/s40248-018-0145-4. eCollection 2018.

7.

Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology?

Galeone C, Scelfo C, Bertolini F, Caminati M, Ruggiero P, Facciolongo N, Menzella F.

Biomed Res Int. 2018 Jun 11;2018:4617565. doi: 10.1155/2018/4617565. eCollection 2018. Review.

8.

Heat-induced necrosis after bronchial thermoplasty: a new concern?

Menzella F, Lusuardi M, Galeone C, Montanari G, Cavazza A, Facciolongo N.

Allergy Asthma Clin Immunol. 2018 Jun 25;14:25. doi: 10.1186/s13223-018-0252-y. eCollection 2018.

9.

Towards precision medicine: The application of omics technologies in asthma management.

Scelfo C, Galeone C, Bertolini F, Caminati M, Ruggiero P, Facciolongo N, Menzella F.

Version 2. F1000Res. 2018 Apr 4 [revised 2018 Jan 1];7:423. doi: 10.12688/f1000research.14309.2. eCollection 2018.

10.

Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma.

Facciolongo N, Di Stefano A, Pietrini V, Galeone C, Bellanova F, Menzella F, Scichilone N, Piro R, Bajocchi GL, Balbi B, Agostini L, Salsi PP, Formisano D, Lusuardi M.

BMC Pulm Med. 2018 Feb 8;18(1):29. doi: 10.1186/s12890-017-0554-8.

11.

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty.

Menzella F, Galeone C, Lusuardi M, Simonazzi A, Castagnetti C, Ruggiero P, Facciolongo N.

Ther Clin Risk Manag. 2017 Nov 8;13:1489-1493. doi: 10.2147/TCRM.S149775. eCollection 2017.

12.

Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?

Menzella F, Lusuardi M, Galeone C, Facciolongo N.

Ther Clin Risk Manag. 2017 Sep 19;13:1213-1221. doi: 10.2147/TCRM.S144604. eCollection 2017. Review.

13.

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

Menzella F, Galeone C, Bertolini F, Castagnetti C, Facciolongo N.

J Asthma Allergy. 2017 Aug 30;10:237-247. doi: 10.2147/JAA.S144100. eCollection 2017. Review.

14.

Real-life Efficacy of Omalizumab After 9 Years of Follow-up.

Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L.

Allergy Asthma Immunol Res. 2017 Jul;9(4):368-372. doi: 10.4168/aair.2017.9.4.368.

15.

Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential.

Menzella F, Lusuardi M, Galeone C, Taddei S, Facciolongo N, Zucchi L.

Ther Adv Chronic Dis. 2016 Nov;7(6):260-277. Epub 2016 Aug 11. Review.

16.

The clinical profile of benralizumab in the management of severe eosinophilic asthma.

Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L.

Ther Adv Respir Dis. 2016 Dec;10(6):534-548. Epub 2016 Sep 9. Review.

17.

Clinical usefulness of mepolizumab in severe eosinophilic asthma.

Menzella F, Lusuardi M, Montanari G, Galeone C, Facciolongo N, Zucchi L.

Ther Clin Risk Manag. 2016 Jun 8;12:907-16. doi: 10.2147/TCRM.S86299. eCollection 2016. Review.

18.

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.

Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L.

J Asthma Allergy. 2015 Oct 8;8:105-14. doi: 10.2147/JAA.S40244. eCollection 2015. Review.

19.

Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report.

Facciolongo N, Menzella F, Lusuardi M, Piro R, Galeone C, Castagnetti C, Cavazza A, Carbonelli C, Zucchi L, Salsi PP.

Multidiscip Respir Med. 2015 Mar 8;10(1):9. doi: 10.1186/s40248-015-0002-7. eCollection 2015.

20.

Tailored therapy for severe asthma.

Menzella F, Lusuardi M, Galeone C, Zucchi L.

Multidiscip Respir Med. 2015 Jan 16;10(1):1. doi: 10.1186/2049-6958-10-1. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center